Latest Safety News

Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.

Spacetalk Ltd reported a 17% revenue decline in FY26 amid a strategic reset, but mobile revenue grew 16% as the company pivots to a software-led family safety platform supported by new telco partnerships.

Broken Hill Mines Limited posted a $48.8 million loss for FY2026, driven by acquisition-related costs and re-compliance expenses, despite a 56% revenue increase reflecting production growth at Rasp and Pinnacles mines.

Ashley Services Group delivered a standout FY26 with revenue up 16.7% to $602.2 million and net profit after tax surging 189.5% to $6.29 million, supported by margin gains across key sectors and a strategic acquisition.

Westgold Resources delivered a landmark FY26 with record gold output, soaring profits, and a strong balance sheet underpinning a 10 cents per share fully franked dividend.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

Virgin Australia Holdings (ASX:VGN) posted a 13.4% rise in underlying EBIT to $753 million for FY26, declaring a fully franked dividend of 7.6 cents per share, its first since relisting. The airline’s transformation program, fleet renewal, and operational resilience underpin its improved financial and customer metrics.

Zimplats Holdings reported a strong FY2026 with revenue climbing 57% to US$1.3 billion and profit before tax soaring 484% to US$387.5 million, driven by higher metal prices, increased ore volumes, and improved operational efficiency.